Thalidomide with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of non-transplant eligible myeloma patients in England. In addition, bortezomib with an alkylating agent and a corticosteroid is recommended as an option for first-line treatment of non-transplant eligible patients who are intolerant to or contraindicated to thalidomide.

 

Download